Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing

Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.

Multiple Sclerosis
NICE Rejects Ocrevus For MS

The UK's National Institute for Health and Care Excellence, NICE, has declined to recommend Roche’s Ocrevus (ocrelizumab) for early primary progressive multiple sclerosis (PPMS) because it is unable to consider indication-based pricing, says Roche.

The company is calling for a change of track so that NICE is able to consider different prices for different...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography